- Previous Close
1,489.70 - Open
1,500.40 - Bid 1,497.20 x --
- Ask 1,495.65 x --
- Day's Range
1,474.30 - 1,503.75 - 52 Week Range
1,042.50 - 1,581.70 - Volume
45,868 - Avg. Volume
59,410 - Market Cap (intraday)
1.209T - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
29.39 - EPS (TTM)
50.95 - Earnings Date May 10, 2024
- Forward Dividend & Yield 13.00 (0.87%)
- Ex-Dividend Date Aug 1, 2024
- 1y Target Est
--
Cipla Limited, together with its subsidiaries, manufactures, develops, and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New ventures segments. It also offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. In addition, the company provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Further, it offers Easylax and Easylax L, a liquid paraffin for constipation. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.
www.cipla.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Industry
Recent News: CIPLA.BO
View MorePerformance Overview: CIPLA.BO
Trailing total returns as of 7/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CIPLA.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CIPLA.BO
View MoreValuation Measures
Market Cap
1.20T
Enterprise Value
1.12T
Trailing P/E
29.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.73
Price/Book (mrq)
4.50
Enterprise Value/Revenue
4.42
Enterprise Value/EBITDA
16.42
Financial Highlights
Profitability and Income Statement
Profit Margin
16.20%
Return on Assets (ttm)
10.53%
Return on Equity (ttm)
16.44%
Revenue (ttm)
254.47B
Net Income Avi to Common (ttm)
41.22B
Diluted EPS (ttm)
50.95
Balance Sheet and Cash Flow
Total Cash (mrq)
56.82B
Total Debt/Equity (mrq)
2.09%
Levered Free Cash Flow (ttm)
1.95B